[Hexoprenalin as a tocolytic drug (author's transl)]

Area of Science:

• Obstetrics and Gynecology
• Pharmacology
• Maternal-Fetal Medicine

Context:

• Premature labor and delivery pose significant risks to both mother and neonate.
• Tocolytic agents are crucial for managing preterm labor and improving perinatal outcomes.
• Hexoprenalin, a beta-sympathomimetic, has been investigated for its efficacy and safety in obstetric applications.

Purpose:

• To evaluate the tocolytic efficacy of hexoprenalin across different obstetric indications.
• To assess cardiovascular side effects, specifically maternal and fetal heart rate changes, associated with hexoprenalin administration.
• To determine optimal dosing strategies for hexoprenalin in managing premature labor and other obstetric emergencies.

Summary:

• Hexoprenalin demonstrated satisfactory tocolytic effects in preventing premature labor via long-term infusion (0.075 mcg/min) and inhibiting established labor (0.33 mcg/min).
• Acute administration (1.0 mcg/min bolus) was adequate for labor inhibition during parturition or as premedication.
• Cardiovascular monitoring, particularly maternal heart rate, indicated dose-dependent effects, with higher doses showing more pronounced increases.

Impact:

• Findings support hexoprenalin's utility as a tocolytic agent in diverse obstetric situations.
• The study highlights the importance of individualized dosing based on the clinical context to balance efficacy and cardiovascular effects.
• Further research may refine hexoprenalin's role in optimizing maternal and fetal outcomes during high-risk pregnancies.